The 2010 Canadian hypertension education program recommendations for the management of hypertension: Part 2 - Therapy

Canadian Journal of Cardiology

Volumn 26, Issue 5, 2010, Pages 249-258

  Hackam, Daniel G ^a   Khan, Nadia A ^b   Hemmelgarn, Brenda R ^c   Rabkin, Simon W ^b   Touyz, Rhian M ^d   Campbell, Norman R C ^e   Padwal, Raj ^f   Campbell, Tavis S ^c   Lindsay, M Patrice ^g   Hill, Michael D ^e   Quinn, Robert R ^e   Mahon, Jeff L ^a   Herman, Robert J ^c   Schiffrin, Ernesto L ^h   Ruzicka, Marcel ⁱ   Larochelle, Pierre ^j   Feldman, Ross D ^a   Lebel, Marcel ^k   Poirier, Luc ^k   Arnold, J Malcolm O ^a   Moe, Gordon W ^l   Howlett, Jonathan G ^m   Trudeau, Luc ⁿ   Bacon, Simon L ^o   Petrella, Robert J ^a   Milot, Alain ^p   Stone, James A ^c   Drouin, Denis ^p   Boulanger, Jean Martin ^q   Sharma, Mukul ^r   Hamet, Pavel ^s   Fodor, George ^t   Dresser, George K ^a   Carruthers, S George ^u   Pylypchuk, George ^v   Burgess, Ellen D ^f   Burns, Kevin D ⁱ   Vallée, Michel ^w   Prasad, G V Ramesh ^x   Gilbert, Richard E ^y   Leiter, Lawrence A ^z   Jones, Charlotte ^e   Ogilvie, Richard I ^aa   Woo, Vincent ^ab   McFarlane, Philip A ^y   Hegele, Robert A ^ac   Tobe, Sheldon W ^a   more..

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF ALBERTA   (Canada)

^g Canadian Stroke Network   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^k LAVAL UNIVERSITY   (Canada)

^l UNIVERSITY HEALTH NETWORK   (Canada)

^m QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

ⁿ MCGILL UNIVERSITY   (Canada)

^o Gina Cody School of Engineering and Computer Science   (Canada)

^p UNIVERSITÉ LAVAL   (Canada)

^q UNIVERSITÉ DE SHERBROOKE   (Canada)

^r UNIVERSITY OF OTTAWA   (Canada)

^s UNIVERSITÉ DE MONTRÉAL   (Canada)

^t UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^u Five Hills Health Region   (Canada)

^v UNIVERSITY OF SASKATCHEWAN   (Canada)

^w MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^x UNIVERSITY OF TORONTO   (Canada)

^y ST MICHAEL'S HOSPITAL   (Canada)

^z ST MICHAEL'S HOSPITAL   (Canada)

^aa TORONTO WESTERN HOSPITAL   (Canada)

^ab UNIVERSITY OF MANITOBA   (Canada)

^ac SUNNYBROOK RESEARCH INSTITUTE   (Canada)

more..

Author keywords

Antihypertensive drugs; Blood pressure; Guidelines; High blood pressure; Hypertension; Lifestyle interventions

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE ANTAGONIST; ALISKIREN; AMPHETAMINE; ANABOLIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COCAINE; CORTICOSTEROID; CYCLOSPORIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ERYTHROPOIETIN; HYDRALAZINE; LOSARTAN; MINOXIDIL; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; RAMIPRIL; RENIN INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TACROLIMUS; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIET; DISEASE ASSOCIATION; EDUCATION PROGRAM; EVIDENCE BASED MEDICINE; EXERCISE; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFESTYLE; LOW FAT DIET; MORBIDITY; MORTALITY; SODIUM INTAKE; STRESS MANAGEMENT;

EID: 77952304299     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)70379-2     Document Type: Article

References (26)

1. Lawes CM, Hoorn SV, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-1518
2. Joffres MR, Hamet P, Rabkin SW, Gelskey D, Hogan K, Fodor G. Prevalence, control and awareness of high blood pressure among Canadian adults. Canadian Heart Health Surveys Research Group. CMAJ 1992;146:1997-2005.
3. Khan N, Wardman D, Campbell N. Differences in need for antihypertensive drugs among those aware and unaware of their hypertensive status: A cross sectional survey. BMC Cardiovasc Disord 2005;5:4.
4. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559 (Pubitemid 351522739)
5. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet 2008;372:1174-1183
6. Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-1237
7. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428
8. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: A cluster randomized, controlled trial. Hypertension 2009;53:646-653
9. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: Meta-analysis of prospective studies. BMJ 2009;339:b4567.
10. McAlister FA. The Canadian Hypertension Education Program - a unique Canadian initiative. Can J Cardiol 2006;22:559-564 (Pubitemid 44044211)
11. Institute of Medicine Panel on Dietary Reference Intakes for Electrolytes and Water. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate/Panel on Dietary Reference Intakes for Electrolytes and Water, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. Washington: National Academies Press, 2009.
12. Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: Observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007;334:885.
13. Joffres MR, Campbell NR, Manns B, Tu K. Estimate of the benefits of a population-based reduction in dietary sodium additives on hypertension and its related health care costs in Canada. Can J Cardiol 2007;23:437-443 (Pubitemid 46977999)
14. Campbell NR, Khan NA, Hill MD, et al. 2009 Canadian Hypertension Education Program recommendations: The scientific summary - an annual update. Can J Cardiol 2009;25:271-277
15. Khan NA, Hemmelgarn B, Herman RJ, et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 2009;25:287-298
16. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-579
17. Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Press 2007;16:13-19 (Pubitemid 46672249)
18. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006;368:1449-1456
19. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-537
20. Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure (ASTRONAUT). ClinicalTrials.gov Identifier: NCT00894387.
21. Parving HH, Brenner BM, McMurray J, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671
22. Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbi-mortality in Patients With Chronic Heart Failure (ATMOSPHERE). ClinicalTrials.gov Identifier: NCT00853658.
23. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardioprotective effects of direct renin inhibition: A systematic literature review. J Hypertens 2009;27:2321-2331
24. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300.
25. McAlister FA, Zarnke KB, Campbell NR, et al. The 2001 Canadian recommendations for the management of hypertension: Part two - therapy. Can J Cardiol 2002;18:625-641
26. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)